EGFR and non-small cell lung carcinoma: Among them, osimertinib is the first FDA-approved EGFR-TKI for patients with EGFR-mutant (EGFRm) NSCLC whose disease has become resistant to first-generation EGFR-TKIs through the T790M mutation as a second-line treatment and for EGFRm advanced NSCLC as a first-line treatment.